SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:0344 0338
 

Sökning: L773:0344 0338 > (2020-2024) > In vitro anti-cance...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005272naa a2200457 4500
001oai:DiVA.org:uu-518359
003SwePub
008231219s2023 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5183592 URI
0247 a https://doi.org/10.1016/j.prp.2023.1548322 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Paudel, Keshav Raju Centenary Inst, Ctr Inflammat, Sydney, NSW 2007, Australia.;Univ Technol Sydney, Fac Sci, Sch Life Sci, Sydney, NSW 2007, Australia.4 aut
2451 0a In vitro anti-cancer activity of a polyherbal preparation, VEDICINALS®9, against A549 human lung adenocarcinoma cells
264 1b Elsevier,c 2023
338 a print2 rdacarrier
520 a PurposeNon-small cell lung cancer (NSCLC) is among the leading causes of morbidity and mortality worldwide. Despite the availability of several treatment options, the five-year survival rate of NSCLC is extremely low (<20%). This underlines the necessity of more effective therapeutic alternatives. In this context, plant-derived extracts and bioactive molecules extracted from plants, known collectively as phytoceuticals, represent an extremely variegated source of bioactive compounds with potent anticancer potential. In the present study, we tested the in vitro anticancer activity of a polyherbal preparation, VEDICINALS®9, containing nine different bioactive principles extracted by medicinal plants.MethodsThe anticancer activity of VEDICINALS®9 was investigated by measuring its impact on A549 human NSCLC cell proliferation (MTT assay and trypan blue staining), migration (wound healing assay and transwell chamber assay) and by measuring the impact on the expression of cancer-related proteins (Human XL Oncology Protein Array).ResultsWe show that VEDICINALS®9 at a concentration of 0.2% v/v has potent anticancer effect, significantly inhibiting A549 cell proliferation and migration. Mechanistically, this was achieved by downregulating the expression of proteins involved in cancer cell proliferation (Axl, FGF basic, enolase 2, progranulin, survivin) and migration (Dkk-1, cathepsins B and D, BCL-x, amphiregulin, CapG, u-plasminogen activator). Furthermore, treatment with VEDICINALS®9 resulted in increased expression of the oncosuppressor protein p53 and of the angiogenesis inhibitor endostatin.ConclusionsTaken together, our results provide proof of principle of the potent anticancer activity of the polyherbal preparation VEDICINALS®9, highlighting its enormous potential as an alternative or adjuvant therapy for lung cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Lung cancer
653 a VEDICINALS (R) 9
653 a Migration
653 a Proliferation
653 a Angiogenesis
7001 a Rajput, Rashiu Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia.4 aut
7001 a De Rubis, Gabrieleu Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia.;Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, NSW 2007, Australia.4 aut
7001 a Allam, Venkata Sita Rama Rajuu Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi4 aut0 (Swepub:uu)venal651
7001 a Williams, Kylie Anneu Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia.4 aut
7001 a Singh, Sachin Kumaru Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, NSW 2007, Australia.;Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara, Punjab, India.4 aut
7001 a Gupta, Gauravu Suresh Gyan Vihar Univ, Sch Pharm, Jaipur, Rajasthan, India.;Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Med Coll, Ctr Global Hlth Res, Chennai, India.;Graph Era Hill Univ, Sch Pharm, Dehra Dun 248007, India.4 aut
7001 a Salunke, Prakashu Vedicinals India Pvt Ltd, Pune, Maharashtra, India.4 aut
7001 a Hansbro, Philip Michaelu Centenary Inst, Ctr Inflammat, Sydney, NSW 2007, Australia.;Univ Technol Sydney, Fac Sci, Sch Life Sci, Sydney, NSW 2007, Australia.4 aut
7001 a Gerlach, Joachimu Vedicinals India Pvt Ltd, Pune, Maharashtra, India.;Verbindungsstr 21, D-40764 Langenfeld, Germany.4 aut
7001 a Dua, Kamalu Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia.;Univ Technol Sydney, Australian Res Ctr Complementary & Integrat Med, Fac Hlth, Ultimo, NSW 2007, Australia.;POB 123, Broadway, NSW 2007, Australia.4 aut
7102 a Centenary Inst, Ctr Inflammat, Sydney, NSW 2007, Australia.;Univ Technol Sydney, Fac Sci, Sch Life Sci, Sydney, NSW 2007, Australia.b Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Sydney, NSW 2007, Australia.4 org
7730 t Pathology, Research and Practiced : Elsevierg 250q 250x 0344-0338x 1618-0631
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-518359
8564 8u https://doi.org/10.1016/j.prp.2023.154832

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy